The groundbreaking nasal spray is eligible for insurance
coverage.
NEW YORK, April 11, 2024 /PRNewswire/ -- Hudson Mind,
an interventional mental health clinic in New York City, announces the addition of
Spravato® (https://mind.hudson.health/treatments/spravato/).
The integration of Spravato opens the door to more accessible
treatment options for patients with major depression.
Spravato is a nasal spray made from a derivative of ketamine
called esketamine, which activates biological processes that boost
the neurotransmitter Glutamate in regions of the brain associated
with mood. Since its FDA approval in 2019, studies have
demonstrated Spravato's fast-acting relief and enduring
efficacy—especially for patients with treatment-resistant
conditions.
The World Psychiatry Journal estimates that at least 30% of
people who have been diagnosed with depression qualify as
treatment-resistant, indicating that they have not responded to two
or more antidepressant trials. Spravato is a natural addition to
Hudson Mind's commitment to bridging the gap between conventional
and cutting-edge care.
Hudson Mind psychiatrist Dr. Marcel
Green is eager to introduce more patients to the burgeoning
interventional mental health landscape, starting with Spravato.
"For too long, patients have felt frustrated by treatment
options limited in precision that have not significantly advanced
in decades. With widespread insurance eligibility, Spravato brings
more precise interventions to the forefront of mainstream,
accessible care," says Dr. Green. "At Hudson Mind, we emphasize
that ketamine represents a revolutionary advancement in mental
health care. Spravato coupled with integration therapy—which helps
translate the experience into real, pragmatic changes— yields a
powerful impact that is noticeable early in treatment. Its
promotion of neuroplasticity within the brain both accelerates and
solidifies the development of new thinking patterns, broadens
emotional range, and forges mental and emotional resiliency."
Spravato joins a range of clinically-proven interventions at
Hudson Mind, including IV ketamine therapy for depression and
anxiety, Transcranial Magnetic Stimulation for depression and
obsessive compulsive disorder, and Stellate Ganglion Blocks for
chronic anxiety and Post-Traumatic Stress Disorder.
About Hudson Mind
Hudson Mind is the interventional
mental health branch of Hudson Health's multidisciplinary practice,
which includes pain management and regenerative & longevity
medicine. Hudson Mind combines conventional psychotherapy and
pharmacology with cutting-edge interventions proven to break
depressive patterns, reset the nervous system, and activate new
neural connections in the brain. The practice is located in
New York City's West Village. To
learn more, please visit mind.hudson.health.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spravato-therapy-at-hudson-mind-ushers-in-new-era-of-accessible-care-for-treatment-resistant-depression-302117484.html
SOURCE Hudson Mind